130 related articles for article (PubMed ID: 17195891)
1. Increased circulatory MMP-2 and MMP-9 levels and activities in patients with type 1 diabetes mellitus.
Shiau MY; Tsai ST; Tsai KJ; Haung ML; Hsu YT; Chang YH
Mt Sinai J Med; 2006 Nov; 73(7):1024-8. PubMed ID: 17195891
[TBL] [Abstract][Full Text] [Related]
2. Elevated circulatory MMP-2 and MMP-9 levels and activities in patients with rheumatoid arthritis and systemic lupus erythematosus.
Chang YH; Lin IL; Tsay GJ; Yang SC; Yang TP; Ho KT; Hsu TC; Shiau MY
Clin Biochem; 2008 Aug; 41(12):955-9. PubMed ID: 18471998
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus.
Derosa G; Avanzini MA; Geroldi D; Fogari R; Lorini R; De Silvestri A; Tinelli C; Rondini G; d'Annunzio G
Diabetes Res Clin Pract; 2005 Nov; 70(2):119-25. PubMed ID: 16188574
[TBL] [Abstract][Full Text] [Related]
4. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
Florys B; Głowińska B; Urban M; Peczyńska J
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases in blood from patients with LAM.
Odajima N; Betsuyaku T; Nasuhara Y; Inoue H; Seyama K; Nishimura M
Respir Med; 2009 Jan; 103(1):124-9. PubMed ID: 18760908
[TBL] [Abstract][Full Text] [Related]
6. Relationships between circulating matrix metalloproteinase-2 and -9 and renal function in patients with chronic kidney disease.
Chang HR; Yang SF; Li ML; Lin CC; Hsieh YS; Lian JD
Clin Chim Acta; 2006 Apr; 366(1-2):243-8. PubMed ID: 16313894
[TBL] [Abstract][Full Text] [Related]
7. Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy.
Jacqueminet S; Ben Abdesselam O; Chapman MJ; Nicolay N; Foglietti MJ; Grimaldi A; Beaudeux JL
Clin Chim Acta; 2006 May; 367(1-2):103-7. PubMed ID: 16426593
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
9. The influence of type I diabetes mellitus on the expression and activity of gelatinases (matrix metalloproteinases-2 and -9) in induced periodontal disease.
Silva JA; Lorencini M; Peroni LA; De La Hoz CL; Carvalho HF; Stach-Machado DR
J Periodontal Res; 2008 Feb; 43(1):48-54. PubMed ID: 18230106
[TBL] [Abstract][Full Text] [Related]
10. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinase-2 and -9 levels in obese patients.
Derosa G; Ferrari I; D'Angelo A; Tinelli C; Salvadeo SA; Ciccarelli L; Piccinni MN; Gravina A; Ramondetti F; Maffioli P; Cicero AF
Endothelium; 2008; 15(4):219-24. PubMed ID: 18663625
[TBL] [Abstract][Full Text] [Related]
12. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
13. Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy.
Roldán V; Marín F; Gimeno JR; Ruiz-Espejo F; González J; Feliu E; García-Honrubia A; Saura D; de la Morena G; Valdés M; Vicente V
Am Heart J; 2008 Jul; 156(1):85-91. PubMed ID: 18585501
[TBL] [Abstract][Full Text] [Related]
14. CD40 expression and its association with low-grade inflammation in a Greek population of type 1 diabetic juveniles: evidence for differences in CD40 mRNA isoforms expressed by peripheral blood mononuclear cells.
Chatzigeorgiou AE; Lembessis PE; Mylona-Karagianni CF; Tsouvalas EA; Diamanti-Kandarakis E; Kamper EF
Exp Clin Endocrinol Diabetes; 2010 Jan; 118(1):38-46. PubMed ID: 19834879
[TBL] [Abstract][Full Text] [Related]
15. Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis.
Lee KY; Kim EH; Yang WS; Ryu H; Cho SN; Lee BI; Heo JH
J Neurol Sci; 2004 May; 220(1-2):73-8. PubMed ID: 15140609
[TBL] [Abstract][Full Text] [Related]
16. MMP-2 and MMP-9 levels in peripheral blood after subarachnoid hemorrhage.
Horstmann S; Su Y; Koziol J; Meyding-Lamadé U; Nagel S; Wagner S
J Neurol Sci; 2006 Dec; 251(1-2):82-6. PubMed ID: 17087971
[TBL] [Abstract][Full Text] [Related]
17. Increased activity of matrix metalloproteinase 2 and 9 after hepatic radiofrequency ablation.
Frich L; Bjørnland K; Pettersen S; Clausen OP; Gladhaug IP
J Surg Res; 2006 Oct; 135(2):297-304. PubMed ID: 16934296
[TBL] [Abstract][Full Text] [Related]
18. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
19. Plasma MMP-2, MMP-9 and N-BNP in long-term survivors following complicated myocardial infarction: relation to cardiac magnetic resonance imaging measures of left ventricular structure and function.
Orn S; Manhenke C; Squire IB; Ng L; Anand I; Dickstein K
J Card Fail; 2007 Dec; 13(10):843-9. PubMed ID: 18068618
[TBL] [Abstract][Full Text] [Related]
20. Association of MMP-2 and MMP-9 with clinical outcome of neurocysticercosis.
Verma A; Prasad KN; Nyati KK; Singh SK; Singh AK; Paliwal VK; Gupta RK
Parasitology; 2011 Sep; 138(11):1423-8. PubMed ID: 21813044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
